Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH PRO: Insulin Degludec vs Glargine in T2D
NCT03687827Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL at 35 weeks. Started Oct 2018; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03687827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687827.